Bumetanide nasal spray had comparable pharmacodynamic effects of diuresis and natriuresis to IV and oral bumetanide. (HealthDay News) — Bumetanide nasal spray (BNS) has statistical bioequivalence to ...

CHICAGO -- A bumetanide nasal spray in development for heart failure was well-tolerated and showed reliable rates of absorption compared with oral and intravenous delivery in a phase I trial of ...

A study testing a new nasal spray form of the medication bumetanide, a commonly prescribed diuretic, was found to be as safe and well-tolerated (meaning with no significant nasal irritation) in ...

A Prescription Drug User Fee Act target date of September 14, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) ...

Enbumyst is not intended for chronic use and should be replaced with oral diuretics as soon as practical. The Food and Drug Administration (FDA) has approved Enbumyst ™, a nasal spray formulation of ...

This news release contains updated information from the researcher that was not in the abstract. CHICAGO, Nov. 18, 2024 — A new nasal spray form of the medication bumetanide may reduce the tissue ...